Wednesday, July 8, 2026

pharma · T Cell Lymphoma · Diabetes Mellitus · CRSP

S.A

S.A is a pharma organization headquartered in San Lorenzo, EU. It trades on NYSE under ticker CRSP. Primary therapeutic focus areas include T Cell Lymphoma, Diabetes Mellitus, Beta-Thalassemia, Sickle Cell Disease, B-cel

San Lorenzo, EU HQ
2011 Founded
50 Employees
Public company Type
CRSP · NYSE Ticker
Company details
Status
Public
HQ
San Lorenzo, EU
Founded
2011
Employees
50
Programs
14
Drugs
8
Patents
65
Clinical program

CTX001

Phase 3 · mab · Beta-Thalassemia

CTX001 for Beta-Thalassemia is a Phase 3 program (mab) at S.A. with 3 ClinicalTrials.gov record(s).

← All S.A. projects Phase 3 mab active

Internal code VX18-CTX001-131

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
S.A.
Phase
Phase 3
Modality
mab
Indication
Beta-Thalassemia
Status
active
Trials
3